Showing results (91-100 of 103) with videos related to
Sort By:
Pageof 11
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 1, 2024
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 studyWhitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation StudyBenoit You, Christopher Purdy, Larry J Copeland, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 29, 2025
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 studyWhitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.Gynecologic Oncology|August 16, 2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experienceKate E Oliver, William E Brady, Michael Birrer, et al.Gynecologic Oncology|August 25, 2023
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancerSandro Pignata, Michael Bookman, Jalid Sehouli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology StudyLarry J Copeland, Mark F Brady, Robert A Burger, et al.Obstetrics and Gynecology|January 12, 2019
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian CarcinomaPeter G Rose, James J Java, Ritu Salani, et al.Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.European Journal of Cancer (Oxford, England : 1990)|February 26, 2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized studyIgnace Vergote, Larry J Copeland, Toon Van Gorp, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian CancerKrishnansu S Tewari, Robert A Burger, Danielle Enserro, et al.Pageof 11